Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
Date:11/3/2009

ebcast can be accessed on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com. A replay of the Webcast will be available on the Company's Web site for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information, please visit http://www.poniard.com.

Forward-Looking Statement

This release contains forward-looking statements, including statements regarding the Company's financial position and results of operations, business objectives and drug development plans; the timing of the Company's announcement of top-line results of its Phase 3 SPEAR trial and the initiation of submission of a rolling NDA if the results are positive; the potential safety and efficacy of the Company's picoplatin products in development; and the Company's capital raising, commercialization and partnering goals and strategies. The Company's actual results may differ materially from those indicated in these fo
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Poniard Pharmaceuticals to Present at the 2009 UBS Global Life Sciences Conference
2. Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target
3. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
4. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
5. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
6. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
7. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
8. Poniard Pharmaceuticals Files Shelf Registration
9. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
10. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
11. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Cambrex Corporation (NYSE: CBM ) reports results for ... Highlights , Second quarter sales increased 59% to ... year. , Second quarter EBITDA increased 86% to $21.2 ... year (see table at the end of this release). ... of foreign currency, to between 13% and 16% over 2013, ...
(Date:7/31/2014)... 2014 Today BioSpace , the leading life sciences employment ... spotlighting the life sciences community in Illinois , ... , Michigan , Minnesota , ... Ohio and Wisconsin . BioMidwest ... all job postings on BioSpace originating in this region in 2013. The ...
(Date:7/31/2014)... part of the mouse brain in a way that ... view. Their imaging technique allows zooming in and out ... enabled the team to watch brain cells light up ... represent a step toward better understanding how our own ... Neuron . , In the past, researchers often ...
(Date:7/31/2014)... 31, 2014 Graphite Metallizing Corporation announces ... oven carts. These bearings are uniquely suited to prevent ... bearings because of the high temperatures . , ... from the design engineers at Graphite Metallizing to overcome ... During their manufacturing operation, pans containing blocks of powder ...
Breaking Biology Technology:Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Midwest Biotech Leaders Featured On BioSpace Map 2New mapping approach lets scientists zoom in and out as the brain processes sound 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3
... Martek Biosciences,Corporation (Nasdaq: MATK ) today announced ... ended October 31, 2008. Revenues for the fourth,quarter were ... fourth quarter of,fiscal 2007. Net income was $10.5 million, ... fiscal 2008 compared with $18.3 million, or $0.55 per,diluted ...
... The University of,Minnesota has received a $40 ... Foundation. Goals for the funding, to be paid over,five ... and to accelerate the timeline to translate it into a ... The gift is the second largest ...
... Olympus has further,cemented its position as a leader ... exclusive and immediate deal to distribute the products of,Irish ... global,provider of ports for state-of-the-art laparoscopic operative techniques via,a ... now the exclusive,distributor for the full range of products ...
Cached Biology Technology:Martek Announces Fourth Quarter and FY 2008 Financial Results 2Martek Announces Fourth Quarter and FY 2008 Financial Results 3Martek Announces Fourth Quarter and FY 2008 Financial Results 4Martek Announces Fourth Quarter and FY 2008 Financial Results 5Martek Announces Fourth Quarter and FY 2008 Financial Results 6Martek Announces Fourth Quarter and FY 2008 Financial Results 7Martek Announces Fourth Quarter and FY 2008 Financial Results 8Martek Announces Fourth Quarter and FY 2008 Financial Results 9Martek Announces Fourth Quarter and FY 2008 Financial Results 10Martek Announces Fourth Quarter and FY 2008 Financial Results 11University of Minnesota Receives $40 Million for Type 1 Diabetes Research 2University of Minnesota Receives $40 Million for Type 1 Diabetes Research 3University of Minnesota Receives $40 Million for Type 1 Diabetes Research 4Minimally Invasive Surgery: Olympus Further Enhances Credentials by Entering Into Exclusive Sales and Distribution Partnership With Market and Technology Leader Advanced Surgical Concepts 2
(Date:7/31/2014)... researchers have completed a 20-year study that looks ... at different times of the year. It finds ... time frame has no measurable negative consequences for ... benefits. , The study was conducted by Gene ... Station fire chief, and Joseph Craine, research assistant ...
(Date:7/31/2014)... exposure to loud noise alters how the brain ... speech sounds, according to neuroscientists at The University ... published this week in Ear and Hearing ... noise-induced hearing loss affects the brain,s recognition of ... all corners of the population, affecting an estimated ...
(Date:7/31/2014)... New Orleans, LA Dr. Oren Tessler, Assistant Professor ... Orleans School of Medicine, is part of a team ... success rate using a method to screen and select ... than 90% of the patients who underwent this surgery ... and also got a bonus cosmetic eyelid surgery. The ...
Breaking Biology News(10 mins):Study finds benefits to burning Flint Hills prairie in fall and winter 2Study finds benefits to burning Flint Hills prairie in fall and winter 3UT Dallas study reveals effect of loud noises on brain 2Surgeons report significant migraine relief from cosmetic eyelid surgery technique 2
... in green tea renowned for their powerful antioxidant ... the eye. Their new report, the first documenting how ... substances, raises the possibility that green tea may protect ... in ACS, bi-weekly Journal of Agricultural and Food ...
... Washington, DC A Georgetown University Medical Center ... National Institute on Drug Abuse to discover and develop ... about nicotine addiction. Kenneth Kellar, PhD, a professor ... five year grant totaling $4.6 million. The theory, ...
... April 2010) -- Ultrasound pioneer Gerald J. Posakony was ... award in the engineering profession on Monday night ... Posakony,s pioneering contributions to the fields of ultrasonics, ... during AAES, 31st annual awards ceremony at the Great ...
Cached Biology News:GUMC to develop smoking cessation aids based on unconventional nicotine addiction theory 2Ultrasound pioneer receives highest award in engineering profession 2Ultrasound pioneer receives highest award in engineering profession 3Ultrasound pioneer receives highest award in engineering profession 4Ultrasound pioneer receives highest award in engineering profession 5Ultrasound pioneer receives highest award in engineering profession 6
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
...
Proliferin (C-14)...
... & Cast submarine gel systems used gasketed gel trays. ... in the tank. Turn it back and run the ... convenience, each Turn & Cast tray is UV transparent. ... edge of the tray and one in the center. ...
Biology Products: